Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Hydromer, Inc. (OTC: HYDI).

Full DD Report for HYDI

You must become a subscriber to view this report.


Recent News from (OTC: HYDI)

Hydromer declares $0.25 dividend
Hydromer ( OTCPK:HYDI ) declares $0.25/share special dividend . More news on: Hydromer, Inc., Dividend News, , Read more ...
Source: SeekingAlpha
Date: September, 19 2018 12:37
The Board of Directors of Hydromer, Inc. Announces a $0.25 per Common Share Dividend
Branchburg, NJ, Sept. 19, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- The Board of Directors of Hydromer, Inc. (HYDI.PK – OTC BB), announces a $0.25 dividend per Common Share with a Record Date of September 24, 2018 and a Dividend Payment Date of October 8, 2018.   Hydromer,...
Source: GlobeNewswire
Date: September, 19 2018 12:24
The Board of Directors of Hydromer, Inc. Announces the Appointment of Peter M. von Dyck as the CEO and President following the Retirement of Manfred F. Dyck
Branchburg, NJ, Sept. 13, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Hydromer, Inc. (HYDI.PK – OTC BB), the "Company" or "Hydromer", announces that the Company's Board of Directors appointed Peter M. von Dyck as Chief Executive Officer and President effective upon the retirement fr...
Source: GlobeNewswire
Date: September, 13 2018 15:05
Hydromer, Inc. Announces the Sale of the T-HEXX Animal Healthcare Product Line to Huvepharma
Branchburg, NJ, Aug. 28, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Hydromer, Inc. (HYDI.PK – OTC BB), the "Company" or "Hydromer", announces that Huvepharma has acquired its T-HEXX Animal Healthcare business. Huvepharma, a fast-growing global pharmaceutical company focused on d...
Source: GlobeNewswire
Date: August, 28 2018 13:28
Hydromer, Inc. Presents: Its Newly Patented Spice Hygiene Technology as an All-Natural, Raw Produce Wash, Designed to Help Prevent the Recent Lettuce E-Coli Outbreak That Sickens Many Americans Each Year
BRANCHBURG, NJ, July 26, 2018 (GLOBE NEWSWIRE) -- Hydromer, Inc. (OTC PINK: HYDI) presents a new technology based on its US Patent on antimicrobial formulations and methods for sanitizing meat products, which has now also shown great merit in potentially combating the recent E-coli outbreak...
Source: GlobeNewswire
Date: July, 26 2018 11:50

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-14N/A0.70N/AN/A0
2018-12-13N/A0.70N/AN/A0
2018-12-12N/A0.70N/AN/A0
2018-12-11N/A0.70N/AN/A0
2018-12-10N/A0.70N/AN/A0

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-074,41630,21614.6148Cover
2018-12-03298932.5843Cover
2018-11-2810,50515,69466.9364Short
2018-11-2711,00011,000100.0000Short
2018-11-231,2001,200100.0000Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on HYDI.


About Hydromer, Inc. (OTC: HYDI)

Logo for Hydromer, Inc. (OTC: HYDI)

Hydromer, Inc is an innovative ISO : technology focused company engaged in the business of inventing, developing, patenting, licensing, manufacturing and selling hydrophilic polymer based products for commercial markets. Hydromer also provides highly specialized medical coating services to industry through its FDA registered and ISO : certified Biosearch Medical Products subsidiary. lt br / gt lt br / gt The goal of Hydromer is to be the leading provider of hydrophilic surface modifications and specialty hydrophilic polymers to industry. While maintaining its industry leadership position in permanent lubricious coatings for medical devices, Hydromer constantly strives to create new, value added technologies and to build upon its current technologies successfully expanding its technology and product base to include drug delivery and infection resistant coatings, anti fog and condensation control coatings for optical plastics and packaging, water resistant film formers for cosmetics, pharmaceutical and animal health products, unique hydrogels for medical, bio surgical and cosmetic applications, and barrier films for the protection of skin from allergens

 

Contact Information

 

 

Current Management

  • Manfred F. Dyck / President, CEO
    • Chairman of the Board of the Company since June and a Director of the Company since its inception. Mr. Dyck served as Chief Executive Officer of the Company from its inception until October , and as of August , reassumed the duties of Chief Executive Officer. Mr. Dyck has been Chief Executive Officer and a Director of Biosearch Medical Products Inc. from to when Biosearch became a wholly owned subsidiary . He holds a B.S. in Chemical Engineering.
  • Robert Lee / CFO, Treasurer, VP, Fin. amp Acct.
    • Mr. Lee earned a MBA in Finance and International Business, and a Bachelor of Science in Accounting and Information Systems, both from New York University s Stern School of Business. His professional experience includes tenure with the New York office of Coopers and Lybrand currently PricewaterhouseCoopers in its Emerging Business Group the Bristol Myers Squibb Internal Auditing group ASARCO s Southern Peru Copper Corporation, now Southern Copper Corporation part of Grupo Mexico and Citigroup s Trading and Capital Markets Division in New York.
  • Martin Dyck / EVP, Ops.
    • Mr. Martin Dyck is the Company s Executive Vice President of Operations and President of the Company s wholly owned subsidiary, Biosearch Medical Products, Inc. Martin C. Dyck is the son of Mr. Manfred F. Dyck. He holds a B.S. in Finance with a minor in Mechanical Engineering.
  • John Konar / Vice President, Director, Human Resources
    • John Konar, Vice President of Quality Assurance since February and Director of Human Resources since with Biosearch Medical Products, Inc. before its acquisition by the Company in , and with both companies thereafter . Since joining Biosearch in , Mr. Konar has been Director of Sales from until , Director of Quality Assurance from to , until promoted to Vice President of Quality Assurance, and Director of Manufacturing of Biosearch from .
  • Manfred F. Dyck / Chairman
    • Chairman of the Board of the Company since June and a Director of the Company since its inception. Mr. Dyck served as Chief Executive Officer of the Company from its inception until October , and as of August , reassumed the duties of Chief Executive Officer. Mr. Dyck has been Chief Executive Officer and a Director of Biosearch Medical Products Inc. from to when Biosearch became a wholly owned subsidiary . He holds a B.S. in Chemical Engineering.

Current Share Structure

  • Market Cap: $2,147,543 - 03/16/2018
  • Authorized: 15,000,000 - 03/15/2018
  • Issue and Outstanding: 4,772,318 - 03/15/2018
  • Float: 2,110,737 - 06/30/2016

 



Daily Technical Chart for (OTC: HYDI)

Daily Technical Chart for (OTC: HYDI)


Stay tuned for daily updates and more on (OTC: HYDI)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: HYDI)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in HYDI is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of HYDI and does not buy, sell, or trade any shares of HYDI. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/